NB-1008 (University of Michigan)

**NB-1008** is an investigational intranasal, nanoemulsion-adjuvanted seasonal influenza vaccine originally developed by NanoBio and continued by BlueWillow Biologics. It combines the licensed inactivated influenza vaccine Fluzone with the W805EC oil-in-water nanoemulsion adjuvant for nasal administration. The formulation is intended to induce influenza antigen-specific mucosal, systemic humoral, and T-helper-1-skewed cellular immune responses; it was evaluated in completed Phase 1 studies in healthy adults using nasal drops and a nasal sprayer. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01333462?viewType=Card))

Other names

Fluzone + 60% W805ECFluzone + W805ECinactivated nasal influenza vaccine NB-1008